Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies

Cancer Causes and Control

Volumn 26, Issue 2, 2015, Pages 257-268

  Yao, Xu ^a   Tian, Zhong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cancer prevention; Colorectal neoplasms; Dyslipidemia; Epidemiology

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CANCER RISK; CELL HETEROGENEITY; COLORECTAL CANCER; DISEASE ASSOCIATION; DOSE RESPONSE; DYSLIPIDEMIA; HUMAN; PRIORITY JOURNAL; PUBLISHING; RISK ASSESSMENT; RISK FACTOR; ALGORITHM; BLOOD; COLORECTAL TUMOR; COMPLICATION; FEMALE; MALE; META ANALYSIS; PROSPECTIVE STUDY; RISK;

ALGORITHMS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COLORECTAL NEOPLASMS; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RISK; TRIGLYCERIDES;

EID: 84925497581     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0507-y     Document Type: Article

References (66)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. International agency for research on cancer, Lyon, France. http://globocan.iarc.fr. Accessed 14 July 2014
2. World Cancer Resarch Fund/American Institue for Cancer Research (2007) Food, nutrition, physical activity and the prevention of cancer: a global perspective. AICR, Washington
3. Bardou M, Barkun AN, Martel M (2013) Obes colorectal Cancer. Gut 62:933–947
4. Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86:s836–s842
5. Esteve E, Ricart W, Fernandez-Real JM (2005) Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 24:16–31
6. Kontush A, de Faria EC, Chantepie S, Chapman MJ (2005) A normotriglyceridemic, low HDL–cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 182:277–285
7. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z et al (2007) Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 37:715–723
8. Avramoglu RK, Basciano H, Adeli K (2006) Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 368:1–19
9. Ghandehari H, Kamal-Bahl S, Wong ND (2008) Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 156:112–119
10. Rosamond W, Flegal K, Furie K et al (2008) Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146
11. Ford ES, Mokdad AH, Giles WH, Mensah GA (2003) Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 107:2185–2189
12. Borena W, Stocks T, Jonsson H et al (2011) Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 22:291–299
13. Inoue M, Noda M, Kurahashi N et al (2009) Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 18:240–247
14. Tulinius H, Sigfusson N, Sigvaldason H et al (1997) Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev 6:863–873
15. Agnoli C, Grioni S, Sieri S et al (2014) Colorectal cancer risk and dyslipidemia: a case–cohort study nested in an Italian multicentre cohort. Cancer Epidemiol 38:144–151
16. Kitahara CM, Berrington DGA, Freedman ND et al (2011) Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 29:1592–1598
17. Tornberg SA, Holm LE, Carstensen JM, Eklund GA (1986) Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N Engl J Med 315:1629–1633
18. Strohmaier S, Edlinger M, Manjer J et al (2013) Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One 8:e54242
19. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M et al (2011) Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European prospective investigation into cancer and nutrition. Gut 60:1094–1102
20. Ahn J, Lim U, Weinstein SJ et al (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18:2814–2821
21. Iso H, Ikeda A, Inoue M et al (2009) Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 125:2679–2686
22. Ahmed RL, Schmitz KH, Anderson KE et al (2006) The metabolic syndrome and risk of incident colorectal cancer. Cancer 107:28–36
23. Bowers K, Albanes D, Limburg P et al (2006) A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 164:652–664
24. Tsushima M, Nomura AM, Lee J, Stemmermann GN (2005) Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci 50:499–505
25. Saydah SH, Platz EA, Rifai N et al (2003) Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 12:412–418
26. Schoen RE, Tangen CM, Kuller LH et al (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91:1147–1154
27. Chyou PH, Nomura AM, Stemmermann GN (1996) A prospective study of colon and rectal cancer among Hawaii Japanese men. Ann Epidemiol 6:276–282
28. Esposito K, Chiodini P, Capuano A et al (2013) Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 44:634–647
29. Law MR, Thompson SG (1991) Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 2:253–261
30. Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86:s836–s842
31. Kritchevsky SB, Kritchevsky D (1992) Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 12:391–416
32. Sidney S, Farquhar JW (1983) Cholesterol, cancer, and public health policy. Am J Med 75:494–508
33. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 339:b2535
34. Schatzkin A, Hoover RN, Taylor PR et al (1988) Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res 48:452–458
35. Wells GA, O’Connell D, Peterson J, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 15 June 2014
36. Wu QJ, Yang Y, Vogtmann E et al (2013) Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Ann Oncol 24:1079–1087
37. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
38. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
39. Hamling J, Lee P, Weitkunat R, Ambuhl M (2008) Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 27:954–970
40. Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482
41. Chene G, Thompson SG (1996) Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 144:610–621
42. Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301–1309
43. Orsini N, Li R, Wolk A et al (2012) Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 175:66–73
44. Royston P (2000) A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med 19:1831–1847
45. Bagnardi V, Zambon A, Quatto P, Corrao G (2004) Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol 159:1077–1086
46. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
47. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
48. Esposito K, Chiodini P, Capuano A et al (2013) Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause 20:1301–1309
49. Esposito K, Chiodini P, Capuano A et al (2013) Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest 36:132–139
50. Wei EK, Giovannucci E, Wu K et al (2004) Comparison of risk factors for colon and rectal cancer. Int J Cancer 108:433–442
51. Sugai T, Habano W, Jiao YF et al (2006) Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J Mol Diagn 8:193–201
52. van Stiphout WA, Hofman A, de Bruijn AM (1987) Serum lipids in young women before, during, and after pregnancy. Am J Epidemiol 126:922–928
53. Munzer T, Harman SM, Sorkin JD, Blackman MR (2009) Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men. J Clin Endocrinol Metab 94:3833–3841
54. Kumagai S, Kai Y, Sasaki H (2001) Relationship between insulin resistance, sex hormones and sex hormone-binding globulin in the serum lipid and lipoprotein profiles of Japanese postmenopausal women. J Atheroscler Thromb 8:14–20
55. McKeown-Eyssen G (1994) Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3:687–695
56. Esteve E, Ricart W, Fernandez-Real JM (2005) Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 24:16–31
57. Erdman SE, Poutahidis T (2010) Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol 38:76–87
58. Kim S, Keku TO, Martin C et al (2008) Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 68:323–328
59. Wu H, Jiang H, Lu D et al (2009) Effect of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery 65:1087
60. van Exel E, Gussekloo J, de Craen AJ et al (2002) Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 51:1088–1092
61. Kontush A, de Faria EC, Chantepie S, Chapman MJ (2005) A normotriglyceridemic, low HDL–cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 182:277–285
62. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z et al (2007) Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 37:715–723
63. Clarke R, Shipley M, Lewington S et al (1999) Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341–353
64. Al-Delaimy WK, Jansen EH, Peeters PH et al (2006) Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers 11:370–382
65. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462–3468
66. Cole BF, Logan RF, Halabi S et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256–266